T cell receptor–major histocompatibility complex class II–peptide complex (TCR–MHC II–peptide complex)

The T cell receptor–major histocompatibility complex class II–peptide complex represents the core structural interface through which CD4+ helper T cells recognize antigens presented by antigen-presenting cells. The complex is formed when a T cell receptor (TCR) binds to a peptide fragment presented by the antigen-binding groove of a major histocompatibility complex class II (MHC II) molecule on the surface of an APC. This interaction is highly specific and determines the activation, differentiation, and function of adaptive immune responses. Structural studies reveal a diagonal docking geometry, with the TCR CDR loops contacting both the MHC and the presented peptide. While this complex is central to immunology and therapeutic strategies (e.g., vaccine and engineered T cell therapies), it is not itself a drug target but rather the site of fundamental immune recognition[1][2][3][5][6][7].

Other names

TCR:pMHC II complexTCR–peptide–MHC class II complexTCR–HLA-DR–peptide complexTCR–pMHC complex

In therapeutics, drugs or biologics generally act by: Enhancing or blocking TCR recognition of peptide–MHC; Modulating T cell activation through auxiliary molecules (CD3, CD4); Redirecting TCR specificity (engineered TCRs); Inhibiting MHC–peptide presentation.